Quoin Pharmaceuticals Provides Clinical And Regulatory Update From Constructive Type C Meeting With U.S. FDA For Qrx003 In Netherton Syndrome
Reuters03-25
Quoin Pharmaceuticals Ltd <2EB0y.F>:: *QUOIN PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY UPDATE FROM CONSTRUCTIVE TYPE C MEETING WITH U.S. FDA FOR QRX003 IN NETHERTON SYNDROME *QUOIN PHARMACEUTICALS LTD - FDA OPEN TO ALTERNATIVE PHASE 3 DESIGN FOR QRX003 WITHOUT TRADITIONAL PLACEBO CONTROL *QUOIN PHARMACEUTICALS LTD - FDA INDICATES SINGLE PHASE 3 STUDY MAY BE SUFFICIENT FOR QRX003 U.S. APPROVAL *QUOIN PHARMACEUTICALS LTD - ON TRACK TO COMPLETE PHASE 3 RECRUITMENT IN 2026, FILE NDA IN 2027 *QUOIN PHARMACEUTICALS LTD - TO SUBMIT PHASE 2 AND PEDIATRIC DATA, REQUEST FDA MEETING BEFORE PHASE 3 QRX003
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments